|Articles|August 10, 2010

EGA Talks Biosimilars

The European Generic Medicines Association's Director for Scientific Affairs, Suzette Cox, talks to us about the environment for biosimilars.

Click here.

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe

Related Content

AstraZeneca Shares Drop Following Wainua’s Failed Heart Disease Trial

ByNicholas Jacobus

July 10th 2026

“AI as Reinvention”: Transforming the Business of Medicine

ByMichael Christel,Emmanuel Frenehard

July 8th 2026

AlzeCure Pharma Enters $2.2 Billion Licensing and Collaboration Agreement with QuantumCell ApS

ByNicholas Jacobus

July 1st 2026

U.S. House Committee Investigating Drugmakers Involved in China Drug Trials: Report

ByNicholas Jacobus

June 30th 2026

Jessica Dunne, US Medical, Autoimmune Diabetes Medical Director at Sanofi

Reading Between the Lines: Closing the T1D Misdiagnosis Gap

ByJessica Dunne

June 26th 2026

EGA Talks Biosimilars

Related Content

AstraZeneca Shares Drop Following Wainua’s Failed Heart Disease Trial

“AI as Reinvention”: Transforming the Business of Medicine

AlzeCure Pharma Enters $2.2 Billion Licensing and Collaboration Agreement with QuantumCell ApS

U.S. House Committee Investigating Drugmakers Involved in China Drug Trials: Report

Reading Between the Lines: Closing the T1D Misdiagnosis Gap

Trending on PharmExec

Launch is Just the Beginning: Rare Disease Care Requires Durability

AstraZeneca Shares Drop Following Wainua’s Failed Heart Disease Trial

FDA Pauses Release of New CRL’s Following Citizen’s Petition

Pharmaceutical Executive Daily: FDA Approves Subcutaneous Sarclisa Escena

FDA Approves Subcutaneous Sarclisa Escena for Multiple Myeloma